These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38780852)

  • 1. Factors associated with the efficacy of first-line nivolumab plus chemotherapy in advanced gastric cancer patients with deficient mismatch repair.
    Park YG; Kim HD; Hyung J; Park YS; Ryu MH
    Gastric Cancer; 2024 Jul; 27(4):840-849. PubMed ID: 38780852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discordant PD-L1 results between 28-8 and 22C3 assays are associated with outcomes of gastric cancer patients treated with nivolumab plus chemotherapy.
    Kim HD; Shin J; Song IH; Hyung J; Lee H; Ryu MH; Park YS
    Gastric Cancer; 2024 Jul; 27(4):819-826. PubMed ID: 38647978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
    Janjigian YY; Shitara K; Moehler M; Garrido M; Salman P; Shen L; Wyrwicz L; Yamaguchi K; Skoczylas T; Campos Bragagnoli A; Liu T; Schenker M; Yanez P; Tehfe M; Kowalyszyn R; Karamouzis MV; Bruges R; Zander T; Pazo-Cid R; Hitre E; Feeney K; Cleary JM; Poulart V; Cullen D; Lei M; Xiao H; Kondo K; Li M; Ajani JA
    Lancet; 2021 Jul; 398(10294):27-40. PubMed ID: 34102137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of changes in serum-based inflammatory indicators to monitor response to nivolumab monotherapy in advanced gastric cancer: a multicenter retrospective study.
    Inukai M; Nishi T; Matsuoka H; Matsuo K; Suzuki K; Serizawa A; Akimoto S; Nakauchi M; Tanaka T; Kikuchi K; Shibasaki S; Uyama I; Suda K
    BMC Cancer; 2024 Sep; 24(1):1121. PubMed ID: 39251991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer.
    Mishima S; Kawazoe A; Nakamura Y; Sasaki A; Kotani D; Kuboki Y; Bando H; Kojima T; Doi T; Ohtsu A; Yoshino T; Kuwata T; Tsuji A; Shitara K
    J Immunother Cancer; 2019 Jan; 7(1):24. PubMed ID: 30704511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.
    Janjigian YY; Ajani JA; Moehler M; Shen L; Garrido M; Gallardo C; Wyrwicz L; Yamaguchi K; Cleary JM; Elimova E; Karamouzis M; Bruges R; Skoczylas T; Bragagnoli A; Liu T; Tehfe M; Zander T; Kowalyszyn R; Pazo-Cid R; Schenker M; Feeny K; Wang R; Lei M; Chen C; Nathani R; Shitara K
    J Clin Oncol; 2024 Jun; 42(17):2012-2020. PubMed ID: 38382001
    [No Abstract]   [Full Text] [Related]  

  • 7. Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer.
    Hagi T; Kurokawa Y; Kawabata R; Omori T; Matsuyama J; Fujitani K; Hirao M; Akamaru Y; Takahashi T; Yamasaki M; Satoh T; Eguchi H; Doki Y
    Br J Cancer; 2020 Sep; 123(6):965-972. PubMed ID: 32616848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma.
    Sun YT; Lu SX; Lai MY; Yang X; Guan WL; Yang LQ; Li YH; Wang FH; Yang DJ; Qiu MZ
    Cancer Immunol Immunother; 2024 Jun; 73(8):144. PubMed ID: 38832979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy.
    Giampieri R; Maccaroni E; Mandolesi A; Del Prete M; Andrikou K; Faloppi L; Bittoni A; Bianconi M; Scarpelli M; Bracci R; Scartozzi M; Cascinu S
    Gastric Cancer; 2017 Jan; 20(1):156-163. PubMed ID: 26796888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood neutrophil-lymphocyte ratio predicts survival for stages III-IV gastric cancer treated with neoadjuvant chemotherapy.
    Jin H; Zhang G; Liu X; Liu X; Chen C; Yu H; Huang X; Zhang Q; Yu J
    World J Surg Oncol; 2013 May; 11():112. PubMed ID: 23705622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neutrophil-Lymphocyte Ratio as a Prognostic Indicator in Patients Treated with Nivolumab for Gastric Cancer].
    Fujita K; Haruki N; Kurehara H; Ochi N; Yamakawa Y; Harata S; Tsumoto C; Tsuji T; Ito T; Izumi A; Usui R; Shinoda N
    Gan To Kagaku Ryoho; 2020 Jun; 47(6):923-926. PubMed ID: 32541169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival.
    Ota Y; Takahari D; Suzuki T; Osumi H; Nakayama I; Oki A; Wakatsuki T; Ichimura T; Ogura M; Shinozaki E; Suenaga M; Chin K; Yamaguchi K
    Cancer Chemother Pharmacol; 2020 Feb; 85(2):265-272. PubMed ID: 31907646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
    Kang YK; Chen LT; Ryu MH; Oh DY; Oh SC; Chung HC; Lee KW; Omori T; Shitara K; Sakuramoto S; Chung IJ; Yamaguchi K; Kato K; Sym SJ; Kadowaki S; Tsuji K; Chen JS; Bai LY; Oh SY; Choda Y; Yasui H; Takeuchi K; Hirashima Y; Hagihara S; Boku N
    Lancet Oncol; 2022 Feb; 23(2):234-247. PubMed ID: 35030335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronological Changes in Neutrophil/lymphocyte Ratio in Advanced Gastric Cancer Patients Treated with Nivolumab: a Report of Nine Cases.
    Nakamura N; Kinami S; Fujita J; Kaida D; Tomita Y; Miyata T; Fujita H; Takamura H; Ueda N; Kosaka T
    Asian Pac J Cancer Prev; 2020 Oct; 21(10):2955-2960. PubMed ID: 33112554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.
    Shitara K; Van Cutsem E; Bang YJ; Fuchs C; Wyrwicz L; Lee KW; Kudaba I; Garrido M; Chung HC; Lee J; Castro HR; Mansoor W; Braghiroli MI; Karaseva N; Caglevic C; Villanueva L; Goekkurt E; Satake H; Enzinger P; Alsina M; Benson A; Chao J; Ko AH; Wainberg ZA; Kher U; Shah S; Kang SP; Tabernero J
    JAMA Oncol; 2020 Oct; 6(10):1571-1580. PubMed ID: 32880601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
    Doki Y; Ajani JA; Kato K; Xu J; Wyrwicz L; Motoyama S; Ogata T; Kawakami H; Hsu CH; Adenis A; El Hajbi F; Di Bartolomeo M; Braghiroli MI; Holtved E; Ostoich SA; Kim HR; Ueno M; Mansoor W; Yang WC; Liu T; Bridgewater J; Makino T; Xynos I; Liu X; Lei M; Kondo K; Patel A; Gricar J; Chau I; Kitagawa Y;
    N Engl J Med; 2022 Feb; 386(5):449-462. PubMed ID: 35108470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy.
    Lee S; Oh SY; Kim SH; Lee JH; Kim MC; Kim KH; Kim HJ
    BMC Cancer; 2013 Jul; 13():350. PubMed ID: 23876227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer.
    Kubota Y; Kawazoe A; Sasaki A; Mishima S; Sawada K; Nakamura Y; Kotani D; Kuboki Y; Taniguchi H; Kojima T; Doi T; Yoshino T; Ishii G; Kuwata T; Shitara K
    Clin Cancer Res; 2020 Jul; 26(14):3784-3790. PubMed ID: 32156744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer.
    Zurlo IV; Schino M; Strippoli A; Calegari MA; Cocomazzi A; Cassano A; Pozzo C; Di Salvatore M; Ricci R; Barone C; Bria E; Tortora G; Larocca LM; Basso M; Martini M
    Cancer Immunol Immunother; 2022 Jan; 71(1):45-55. PubMed ID: 34009410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.